Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study |
Type de publication | Journal Article |
Year of Publication | 2019 |
Auteurs | Hequet D, Huchon C, Soilly A-L, Asselain B, Berseneff H, Trichot C, Combes A, Alves K, Nguyen T, Rouzier R, Baffert S |
Journal | PLOS ONE |
Volume | 14 |
Pagination | e0210917 |
Date Published | JUL 10 |
Type of Article | Article |
ISSN | 1932-6203 |
Résumé | Introduction The organization of health care for breast cancer (BC) constitutes a public health challenge to ensure quality of care, while also controlling expenditure. Few studies have assessed the global care pathway of early BC patients, including a description of direct medical costs and their determinants. The aims of this multicenter prospective study were to describe care pathways of BC patients in a geographic territory and to calculate the global direct costs of early stage BC during the first year following diagnosis. Methods OPTISOINS01 was a multicenter, prospective, observational study including early BC patients from diagnosis to one-year follow-up. Direct medical costs (in-hospital and out-of-hospital costs, supportive care costs) and direct non-medical costs (transportation and sick leave costs) were calculated by using a cost-of-illness analysis based on a bottom-up approach. Resources consumed were recorded in situ for each patient, using a prospective direct observation method. Results Data from 604 patients were analyzed. Median direct medical costs of 1 year of management after diagnosis in operable BC patients were (sic)12,250. Factors independently associated with higher direct medical costs were: diagnosis on the basis of clinical signs, invasive cancer, lymph node involvement and conventional hospitalization for surgery. Median sick leave costs were (sic)8,841 per patient and per year. Chemotherapy was an independent determinant of sick leave costs ((sic)3,687/patient/year without chemotherapy versus (sic)10,706 with chemotherapy). Forty percent (n = 242) of patients declared additional personal expenditure of (sic)614/patient/year. No drivers of these costs were identified. Conclusion Initial stage of disease and the treatments administered were the main drivers of direct medical costs. Direct non-medical costs essentially consisted of sick leave costs, accounting for one-half of direct medical costs for working patients. Out-of-pocket expenditure had a limited impact on the household. |
DOI | 10.1371/journal.pone.0210917 |